Turning Negatives to Positives in Drug Discovery.
Turning Negatives to Positives in Drug Discovery.
Research Interests: The Moraski group has long been interested in inhibiting human health pathogens, with a particular emphasis on mycobacteria, including M. tuberculosis, M. avium, and M. abscessus. As a career medicinal chemist, he makes drug-like molecules and screens them for efficacy, which is paramount in his group’s antibacterial research.
Medicinal Chemistry Project: The Moraski lab has long-standing collaborations and a publication record with many well-known scientists, including Marvin Miller (chemist and academic mentor) and Jeff Schorey (microbiologist) at the University of Notre Dame; Scott Franzblau (Director, Institute for Tuberculosis Research, University of Illinois at Chicago); Michael Berney (microbiologist, Albert Einstein University); Kevin Pethe (Director, Ineos Oxford Institute); and Gerhard Gruber (molecular biologist, Nanyang Technological University). His projects have received direct and indirect support from the NIH, Hsiri Therapeutics, Shionogi, and Eli Lilly. He is lucky to keep connections with many former colleagues from the industry, particularly Joe Lyssikatos.